22 results about "Microvesicles" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

A device, system and process involve conducting electroporation of microvesicles or exosomes or other target structures in a microfluidic arrangement at pressures that exceed atmospheric pressure. Single as well as multiple flow configurations can be employed. In some cases, the system and its operation are computer-controlled for partial or complete automation.

The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and / or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and / or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

Disclosed herein are minimal arrestin domain containing protein 1 (ARRDC1) constructs, which drive the formation of ARRDC1-mediated microvesicles (ARMMs). These vesicles can be harnessed to package and deliver a variety of molecular cargos such as small molecules, nucleic acids, and proteins. An example of such cargo is the genome editor Cas9.

The invention relates to a construction method and application of mycobacterium tuberculosis lipoprotein labeled microvesicles, and belongs to the technical field of biological medicines. According to the invention, an extracellular structural domain of mycobacterium tuberculosis lipoprotein LpqH is fused with a transmembrane region and an intracellular region of vesicular stomatitis virus G protein through a genetic engineering means, and an LpqH48-159-VSVG fusion expression vector is constructed. After the carrier is transfected to mammalian cells, the microvesicles of which the surfaces are specifically marked with LpqH48-159 can be separated from cell culture supernatant by combining with an optimized gradient centrifugation method. The prepared microvesicles specifically target macrophages, and can be used as a novel carrier of mRNA vaccines, and experiments prove that the immune effect and the protective efficacy of the carrier in prevention of EV71 virus infection are significantly superior to those of traditional lipid nanoparticles, which reveals that the microvesicles provided by the invention have wide application prospects in the field of immunotherapy.

The application relates to the technical field of biological medicine manufacturing, and discloses a controlled-release type preparation composition for realizing ovary function recovery, which comprises a core active unit, a moisturizing slow-release unit and a plant extract component. The core active unit is an anisotropic core-shell structure microcapsule with asymmetric charge distribution, which is composed of chitosan, polyglutamic acid and an internal compound, and a layer of outwardly radiating carboxyl brush-shaped molecular chain is distributed on the surface of the core active unit. The moisturizing slow-release unit comprises a polymer skeleton formed by rosmarinic acid and hyaluronic acid, and the polymer skeleton internally occludes elemene. The application utilizes a kinetic restriction mechanism to construct an anisotropic surface layer topology, avoids mucus protein adsorption, induces anti-inflammatory immune regulation by physically adapting mucosal receptors, the moisturizing slow-release unit firstly constructs a physical barrier to repair damage, and the core active unit is used to realize component graded controlled release.

The invention is suitable for the technical field of biological medicine, and provides a cell microvesicle based on freezing extraction and an extraction method and application thereof, ginsenoside Rh2 is used for pre-stimulating human umbilical cord mesenchymal stem cells (hUC-MSCs), a freezing extraction technology is used for extracting cell-derived frozen microvesicles (CDCs), and the novel engineered vesicles Rh2-CDCs are prepared. The method can effectively improve in-vivo blood coagulation and fibrinolytic system functions, reduce multi-organ injury, improve the treatment effect and improve the biological stability of nano-drug treatment, and the freezing extraction technology not only greatly shortens the extraction time and reduces the production cost, but also can obtain the microvesicles with higher concentration, so that the microvesicles have better application prospects. The technical bottleneck of the traditional exosome in application is expected to be overcome; besides, the freezing extraction technology is also suitable for vesicle extraction of other types of cells, and the extracted CDCs can be used as a nano-particle platform to deliver other drugs and active ingredients, so that the freezing extraction method has a wide application prospect.

The present invention provides methods, systems, compositions, and strategies for the use of ARMM-mediated delivery of molecules (e.g, biological molecules, small molecules, proteins, and nucleic acids), to cells of the nervous system. In particular, the present invention generally relates to compositions and methods of producing, testing, and administering ARRDC1-mediated microvesicles (“ARMMs”) to peripheral nervous system cells in mammalian subjects.

The invention relates to an impact-resistant PE pipe and a preparation method thereof, and belongs to the technical field of polymer composite materials. The PE pipe is prepared from the following components in percentage by weight: 6.2 to 9.5 percent of calcium carbonate whisker, 4.4 to 5.8 percent of impact modifier, 0.2 to 0.3 percent of lubricant, 0.15 to 0.2 percent of antioxidant, 0.11 to 0.14 percent of ultraviolet light absorber, 2.6 to 3.2 percent of color master batch and the balance of polyethylene resin, a disulfide structure in a molecular chain of the anti-impact modifier is loaded among the calcium carbonate whiskers through chelation in a multi-point anchoring mode to form a strengthening and impact energy dispersing network, and meanwhile, polycyclohexyl chain segments in the molecular chain form a large number of microvesicle unit structures on the surfaces of the calcium carbonate whiskers. Impact energy is absorbed and is uniformly dispersed and transitionally transmitted by slippage deformation of the vesicle structure, so that the impact resistance of the PE pipe is effectively improved.

Therapeutic formulations and protocols for enhancement of hepatic regeneration, reduction / reversion of liver failure, and restoration of hepatic characteristics of young liver including augmented production of digestive enzymes, production of complement, and detoxificiation. In one embodiment endothelial progenitor cells are cultured in vitro under conditions capable of stimulating enhanced production of microvesicles such as exosomes and / or regenerative factors. Endothelial cells can be activated to produce regenerative factors and / or exosomes by exposure to toll like receptor agonists. Endothelial cells may be autologous, allogeneic or xenogeneic to the recipient.

The invention discloses a mononuclear cell knapsack delivery system of targeted aortic dissection tissue as well as a preparation method and application of the mononuclear cell knapsack delivery system. A'mononuclear cell knapsack type delivery system 'is constructed, a drug is firstly wrapped in tiny vesicles or nanoparticles (NPs) and is non-covalently adhered to the surfaces of mononuclear cells through a reversible metal-polyphenol network formed by ferric ions, tannic acid and the like, and after intravascular administration, the mononuclear cells reach interlayer lesion tissues along with blood flow, so that the mononuclear cells can be quickly delivered to the surface of the mononuclear cells. The drug is migrated and enriched by chemotaxis of focus inflammatory factors, cell factors and the like, and the drug is released in a focus microenvironment, so that the purposes of actively targeting aortic dissection tissues and effectively treating aortic aneurysm and dissection are achieved. The mononuclear cell knapsack-type targeted delivery system provided by the invention does not destroy biological functions of mononuclear cells, can stably load nano-drugs and realize effective drug release in an interlayer or an interlayer early-stage lesion tissue, and shows a good clinical application prospect.

The invention provides a mitochondrial in-vitro activity retention agent, a preparation method and application, and belongs to the technical field of mitochondrial activity preservation. According to the mitochondrial in-vitro activity retention agent, a mitochondrial membrane structure is stabilized through the SS-31 peptide, active oxygen is removed from the source by the rosmarinic acid derivative, a reducing environment is maintained by the reduced glutathione, and an energy metabolism substrate is supplemented by the nicotinamide ribose, so that the mitochondrial in-vitro activity retention agent has a multi-mechanism synergistic effect; the biological activity of the separated mitochondria can be effectively maintained in the in-vitro extraction, purification and preservation process, and the preservation rate of key indexes such as mitochondrial membrane potential and ATP generation rate is remarkably increased to 85% or above. The mitochondrial in-vitro activity retention agent can be used for in-vitro purification, purification and preservation of mitochondria or preparation of stem cell-derived mitochondrial microvesicles, and provides core raw material guarantee for development of products such as efficient anti-aging cosmetics.

This disclosure belongs to the field of biotechnology and specifically relates to a method for constructing an saRNA microvesicle delivery system. The method comprises the steps of (1) designing an saRNA expression vector 1 and a membrane protein expression vector 2, (2) co-transfecting an expression vector 1 and an expression vector 2 into a host cell, and (3) culturing the host cell and isolating microvesicles containing saRNA, wherein the saRNA contains a target gene sequence, the replicon of the saRNA expression vector is an alphavirus replicon, and the microvesicles do not contain a capsid protein. This system can efficiently deliver saRNA into cells or the body and achieve the expression of a target protein. Furthermore, by improving different elements of this delivery system, a highly efficient and less immunogenic modular platform for different diseases and targets can be developed. This delivery system has the potential to complement existing viral and lipid nanoparticle delivery vector toolkits and shows promising future application potential.

The application discloses a kind of based on de-nucleated stem cell's promoting repair microvesicle and its preparation method and application, including the following steps: using cytochalasin B to de-nucleate stem cell, using Percoll centrifugation or vortex method separates the stem cell cytoplast of de-nucleated stem cell, using extrusion device with filter membrane repeatedly extruding, namely de-nucleated stem cell microvesicle.The method in the application removes the nucleus of stem cell while retaining the key protein and RNA of stem cell to play the function of promoting repair, reduces the risk of dangerous gene transfer.Moreover, based on extrusion method can effectively control the particle size distribution of microvesicle, and based on the size of filter membrane pore size, the size of the prepared microvesicle is flexibly adjusted, and has significant therapeutic effect in tissue damage and the like.

The invention relates to a method of enriching Muse cells and obtaining the exosomes, microvesicles, or the secretome therefrom, in several embodiments, the exosomes, microvesicles, secretome or Muse cells may be used in therapeutic methods or non-therapeutic methods.

Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.

The present invention provides methods, systems, and compositions for ARMM-mediated delivery of molecules of interest (e.g., therapeutic agents) to cells and tissues of the eye. The present invention further relates to compositions and methods of producing, testing, and administering ARRDC1-mediated microvesicles (“ARMMs”) to internal structures of the eye. More particularly, the present invention provides compositions and methods of producing, testing, and administering ARMMs particles comprising one or more therapeutic agents (e.g., biological molecules including, but not limited to, CRISPR / Cas9 and other similar endonucleases, base editors, small molecules, proteins, and nucleic acids (e.g., DNA, RNA, siRNA, mRNA, miRNA, and the like)). Also provided are methods of administering therapeutic agents associated with ARMMs, including, but not limited to, methods of treating or contacting cells and tissues of the eye in one or more dosing regimens. In particular, the present invention provides methods of administering therapeutic agents via ARMMs to the cells and tissues that comprise the retina or into the subretinal space. Additionally, the present invention relates to methods of manufacturing (e.g., culturing, clarifying, separating, and concentrating) the inventive compositions from stable producer cell lines and from cell cultures.